A systematic review examining quality of life following pelvic exenteration for locally advanced and recurrent rectal cancer

2017 ◽  
Vol 19 (5) ◽  
pp. 430-436 ◽  
Author(s):  
E. Rausa ◽  
M. E. Kelly ◽  
L. Bonavina ◽  
P. R. O'Connell ◽  
D. C. Winter
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Rectal Cancer ◽  
Pelvic Exenteration ◽  
Locally Advanced ◽  
Recurrent Rectal Cancer

Outcomes of pelvic exenteration for locally advanced primary rectal cancer: Overall survival and quality of life

2016 ◽  
Vol 42 (6) ◽  
pp. 823-828 ◽  
Author(s):  
A.J. Quyn ◽  
K.K.S. Austin ◽  
J.M. Young ◽  
T. Badgery-Parker ◽  
L.M. Masya ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rectal Cancer ◽  
Overall Survival ◽  
Pelvic Exenteration ◽  
Locally Advanced ◽  
Primary Rectal Cancer

scholarly journals Double-barrelled wet colostomy formation after pelvic exenteration for locally advanced or recurrent rectal cancer

2016 ◽  
Vol 18 (11) ◽  
pp. O427-O431 ◽  
Author(s):  
A. L. A. Bloemendaal ◽  
R. Kraus ◽  
N. C. Buchs ◽  
F. C. Hamdy ◽  
R. Hompes ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Pelvic Exenteration ◽  
Locally Advanced ◽  
Recurrent Rectal Cancer

scholarly journals Laparoscopic Total Pelvic Exenteration for Locally Advanced or Recurrent Rectal Cancer

2019 ◽  
Vol 72 (10) ◽  
pp. 559-566
Author(s):  
Kei Kimura ◽  
Masataka Ikeda ◽  
Jihyung Song ◽  
Michiko Hamanaka ◽  
Akihito Babaya ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Pelvic Exenteration ◽  
Locally Advanced ◽  
Recurrent Rectal Cancer ◽  
Total Pelvic Exenteration

Longitudinal trajectory of cancer survivorship in patients with recurrent rectal cancer: Anatomy of recurrence in relation to quality of life and pain.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 679-679
Author(s):  
Tarik Sammour ◽  
Songphol Malakorn ◽  
George J. Chang ◽  
Miguel A. Rodriguez-Bigas ◽  
Brian Bednarski ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rectal Cancer ◽  
Cancer Survivorship ◽  
Recurrent Rectal Cancer ◽  
Pain Scores ◽  
Patient Reported ◽  
Eortc Qlq ◽  
Surgical Salvage

679 Background: Multiple treatment modalities are utilized for patients with recurrent rectal cancer (RRC). While recurrent pelvic tumor can be highly symptomatic, treatments often carry significant morbidity risks. Patient reported outcomes such as quality of life (QoL) and pain can supplement traditional clinical endpoints in assessing the effectiveness of salvage treatments, and thus aid in treatment decision making. We aimed to examine the longitudinal trajectory of cancer survivorship in RRC. Methods: A prospective protocol enrolled patients diagnosed with RRC between 2008 and 2015. Participants prospectively self-reported QoL (measured by the validated EORTC QLQ-C30 and EORTC QLQ-CR29) and pain (measured by the Brief Pain Inventory, BPI), at presentation, and then every 6 months for 5 years. After accounting for repeated measures, trajectory of mean scores over time was assessed for patients amenable to surgical salvage vs those who were not, using linear mixed-effects modeling. Results: A total of 104 patients were enrolled of which 73 (70.2%) were amenable to salvage surgery with curative intent. Surgical salvage was associated with 30 day morbidity of 68.5% (13.7% and 5.5%, Grade 3 and 4 respectively). Three year overall survival was 56.7% (68.5% in surgical and 29.0% in non-surgical patients). Mean baseline QoL scores did not differ between surgical vs nonsurgical patients but were significantly impacted by the anatomical site of recurrent disease (lowest scores in posterior pelvic recurrence; P=0.012). On longitudinal analysis with a median followup of 33 months, surgically salvaged patients showed gradual sustained improvement in QoL but not pain scores. Anatomy of initial recurrence had an ongoing impact on QoL long term with posterior recurrences having the worst scores. Both QoL and pain scores worsened in patients not amendable to surgical salvage. Conclusions: Disease anatomy determines QoL at baseline and long term in patients with RRC. Surgery improves QoL but not pain in selected resectable cases.

Clinical downstaging and quality of life after neoadjuvant chemotherapy in patients with locally advanced rectal cancer: Interim analysis from a phase II clinical trial.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15178-e15178
Author(s):  
Ahmed Abdalla ◽  
Amr M. Aref ◽  
Amer Alame ◽  
Danny Ma ◽  
Mohammed Barawi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Rectal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Phase Ii ◽  
General Health ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer

e15178 Background: The role of neoadjuvant FOLFOX in achieving clinical downstaging and improvement in quality of life (QOL) in patients with locally advanced rectal cancer (LARC) remains to be established. We are conducting a phase II prospective clinical trial to evaluate the use of six cycles of FOLFOX as neoadjuvant chemotherapy in patients with T2-T3/N0-N+ rectal cancer. We now report tumor clinical downstaging and patient-reported QOL in our first patient cohort. Methods: Eleven Patients enrolled in our phase II prospective trial. Patients received three months of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) administered every two weeks. After three weeks of recovery, each patient was treated with conventional chemo-radiotherapy (5FU or capecitabine) All patients had an MRI and endorectal ultrasound at baseline and after completion of FOLFOX. A compilation of validated QOL questionnaires were also administered before and after FOLFOX. Results: A total of 11 patients completed the chemotherapy regimen. Based on pelvic MRI, complete clinical response (T0N0) was achieved by seven patients (64%), one patient (9%) was clinically downstaged but three (27%) didn’t have any changes following FOLFOX. Importantly, we found no disease progression during the FOLFOX course. QOL assessment after FOLFOX regimen showed trend towards improvement in general health, mobility, bladder control and psychological health. These changes in QOL were not statistically significant due to the small sample size. Patients self-grading of their general health before starting FOLFOX was 50% compared to 75% after. Of the five patients with pain at time of diagnosis, four reported complete pain relief while the fifth reported improvement from extreme to moderate pain. Three patients reported improvement in their anxiety/depression. In terms of bowel function, although there was trend towards improvement in the urgency subscale, other bowel functions subscales were unchanged. In general, scores for mobility, selfcare, and bladder function were slightly better after FOLFOX. Conclusions: This study suggests that adding only six cycles of neoadjuvant FOLFOX before CRT not only resulted in clinical downstaging of (LARC) but showed a trend toward improved QOL. This result provides some reassurance for oncologists that this approach does not diminish QOL with no risk of disease progression during the time of neoadjuvant chemotherapy. These findings need to be validated in a larger phase III trial.

scholarly journals The Quality-of-Life Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

2013 ◽  
Vol 85 (1) ◽  
pp. e15-e19 ◽  
Author(s):  
Joseph M. Herman ◽  
Amol K. Narang ◽  
Kent A. Griffith ◽  
Mark M. Zalupski ◽  
Jennifer B. Reese ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rectal Cancer ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Neoadjuvant Chemoradiation
Sign in / Sign up

Export Citation Format

Share Document